Importantly, plasmatic human IL-6 concentrations dramatically decreased upon mouse treatment with gemcitabine + SOM230 bi-therapy in both orthotopic xenografted models (cancer cell and CAF, Fig7D, and patient-derived tumours, Fig7E), whereas mouse IL-6 plasmatic concentrations were comparatively very low and not affected (not shown). This evidence concerns the gene IL6 and neoplasm.